A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
PHASE2CompletedINTERVENTIONAL
Enrollment
27
Participants
Timeline
Start Date
October 12, 2016
Primary Completion Date
September 30, 2020
Study Completion Date
July 1, 2021
Conditions
Advanced Cancers
Interventions
DRUG
LY2606368
Trial Locations (1)
02115
Dana Farber Cancer Institute, Boston
All Listed Sponsors
lead
Dana-Farber Cancer Institute
OTHER
NCT02873975 - A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency | Biotech Hunter | Biotech Hunter